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INTRODUCTION 
The field of solid organ transplantation is based largely on the concept that replacement 
of irreversibly damaged organ in an otherwise 'healthy" recipient can significantly pro-
long survival or even cure some diseases. Although the hope for clinical success is based 
on this premise. many allograft recipients suffer from recurrence of the original disease. 
For example. chronic viral hepatitis types Band C almost invariably attack the new 
liver after hepatic replacement [I. 2]. This unfortunate reality illustrates the importance 
of a systemic. or nonlocal. perspective in transplantation biology: a specific disease may 
primarily manifest in a single organ. but for many disorders this simply represents a 
local manifestation of a more pervasive problem. An exception to this generalization is 
organ-specific toxic injury or organ-based metabolic diseases where replacement of the 
defective organ corrects a systemic problem and brings about a true cure. 
A systemic perspective is also of importance in the study of transplantation physiol-
ogy. including allograft immunobiology. For example. insulin secreted by islet allo-
grafts can regulate the recipient blood sugar: and a new liver will receive blood and 
nutrients from the recipient intestines. from which it will synthesize cholesterol used to 
construct new 'recipient' cells. Fortunately. clinical physicians rarely have to be con-
cerned about physiological compatibility between the donor and recipient. Most of the 
complex systems involved have 'nonlocal' properties that enable a donor organ to 
spontaneously adjust to its new environment. The integration occurs so naturally 
that one rarely even thinks about the interface between donor and recipient. unless 
something goes wrong. 
The most important exception to the above generalization is the immune system: its 
'local' properties result in an inability to spontaneously integrate the donor with the 
recipient. and vice versa. which in turn leads to significant problems for the transplant 
surgeon. Unless the patient is heavily immunosuppressed, the allograft is eventually 
rejected. There are. however. situations in experimental animals where allografts are 
accepted without immunosuppression. and in humans where immunosuppression can 
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be completely withdrawn and the allografts function for the lifetime of the recipient. 
Thus. the local properties of the immune system were not designed to frustrate transplant 
clinicians. instead. they can be predictably redesigned under certain circumstances. 
Consequently. the entire field of clinical transplantation could be thought of as an 
experiment conducted to investigate the local properties of the immune system. among 
others. including the role of MHC antigens and the consequences of MHC antigen 
expression on different cell types. Since these antigens. as well as sex chromosomes. can 
be used to mark the genetic fidelity of an individual cell. double labeling techniques can 
be used to trace specific donor and recipient cell types after solid organ transplantation 
to assess problems with integration. Discoveries made using this technology have 
brought together two previously unlinked research fields in transplantation immun-
ology: the deleterious and the beneficial functions of donor hematolymphoid cells. 
The sections below overview both lines of investigation and highlight the role of den-
dritic cells (DC) in allograft rejection and acceptance. 
ORGAN-BASED IMMUNE NETWORKS 
Before proceeding directly to a discussion of the role of DC in transplantation. it is 
important first to briefly overview organ-based immune physiology. This refers to a 
dynamic network of hematolymphoid cells that travel into and out of. and transiently 
occupy. the interstitium of all solid organs. These cells monitor the microenvironment 
and communicate with central lymphoid organs. and regional lymph nodes via the 
circulatory system and lymphatics [3]. An understanding of this system is of particular 
importance in organ transplantation. since problems with assimilation of the donor 
immune system affect many aspects of transplantation biology. as well as patient man-
agement. Examples include the susceptibility to rejection. the clinical and histopatho-
logical manifestations of both acute and chronic rejection. infections. and the interface 
between infection and rejection. 
Organ-based immune cells are primarily derived from progenitors that migrate from 
the bone marrow. although maturation from local precursors. including intraorgan 
hematopoietic stem cells. can also contribute to this pool. Even in an adult. the liver 
has enough hematopoietic stem cells to fully reconstitute. for the long term. a lethally 
irradiated recipient [4.5]. The important point is that intraorgan immune cells are a 
dynamic population: they continuously mature and migrate and therefore must ulti-
mately be maintained by a stem cell population. 
Normal physiology accounts for the considerable variation among different organs in 
the quantity and quality of organ-based immune cells [6.7]. Organs in direct contact 
with the external environment. such as the lungs and intestines. have an exaggerated 
complement of organ-associated lymphoid tissue. generally termed 'mucosal-associated 
lymphoid tissue'. After contact with commensal bacteria in neonatal life. the immune 
cells spontaneously arrange into an organized complex structure. which is identical to 
that seen in lymph nodes. replete with B cell follicles and T cell-rich interfollicular 
zones rich in DC [8-10]. Thereafter. a delicate balance is maintained between reaction 
to antigens from the environment and local tissue damage. The liver. on the other hand. 
is indirectly exposed to the external environment. since it drains blood from the intes-
tines. It is richly endowed with a large component of cells from the monocyteimacro-
phage lineage. consistent with its role as a filter of various opsonized materials. 
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including microorganisms. activated platelet aggregates. and coagulated proteins [II]. 
Heart [6.7.12.13] and kidneys [6.14.15) also have considerable. but less well developed 
immune networks in comparison to the above organs. 
Common to vascularized organs is a population of DC precursors at various stages 
of maturation located in the interstitial connective tissue [14-19]. The 'immature' state 
of many intraorgan DC [18.20-22]. except for those in the lymphoid tissue of the lung 
and intestines [18.19J. is characterized by phagocytic capacity. which is absent in 
mature DC [U-'. 21. 22): relatively inefficient stimulatory capacity in a mixed leukocyte 
reaction (MLR) [22J: and low density of MHC class II (21) or costimulatory molecule 
expression [19J. Organ-based DC precursors can also he identified with a series of 
monoclonal antibodies directcd at certain differentiation markers. covered elsewhere 
in this book. 
Dendritic cells and their precursors reside near terminal lymphatics throughout the 
interstitium of organs. and are concentrated near draining efferent lymphatic vessels in 
the adventitia of arteries: epithelial-lined conduits that are in contact with the external 
environment, such as the mucosal-associated lymphoid tissue of the lungs [23] and 
intestines [18. 19]: and portal tracts of the liver [17.21. 24). At these sites. they monitor 
the microenvironment for foreign. or dangerous antigens [25]. exposure to which sti-
mulates DC maturation and migration via efferent lymphatics to the paracortex of 
regional lymph nodes where they stimulate a T cell response [18.22.26-30]. The factors 
involved in DC activation. maturation, and migration are covered in more detail in 
Chapter II. Thus. the vasculature and lymphatics represent important lines of commu-
nication between the intraorgan immune network. the regional lymph nodes. and even-
tually the thymus and spleen. 
HEMATOLYMPHOID ANO DENDRITIC CELLS AS POTENTIATORS AND 
FACILITATORS OF REJECTION 
Acute 'Cellular' Rejection 
When an organ becomes an allograft. the nascent hematolymphoid cells become known 
as 'passenger leukocytes'. The idea that these particular donor cells are especially 
immunogenic was first proposed by Snell [31]. Steinmuller (32) provided experimental 
evidence for this concept by showing that chimeric donor skin allografts in which the 
passenger leukocytes were allogeneic. but the epidermal cells were syngeneic to the 
recipient. resulted in permanent graft acceptance. However. the recipients became sen-
sitized to the alloantigens on the hematopoietic cells. 
The relative importance of passenger leukocytes in precipitating rejection was further 
addressed by Guttmann et al. [33], who constructed chimeric donor organs by lethally 
irradiating rats and reconstituting them with allogeneic bone marrow. He showed 
that the 'immunogenicity' of the organs could be greatly reduced when the passenger 
leukocytes were syngeneic to the recipient. Several other experimental manipulations 
also showed conclusively that the passenger leukocytes were more immunogenic than 
the parenchyma. These included pretransplant ill l'itro culturing to eliminate or reduce 
the complement of passenger leukocytes [34-36). and so-called 'parking' experiments 
[37-40]. In the latter. allografts are transplanted into intermediate hosts that are kept 
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immunosuppressed or are naturally immuno-incompetent for one reason or another. 
Once the original passenger leukocytes have been replaced. the composite grafts are 
then retransplanted into a second recipient. that is syngeneic with either the paren-
chymal and stroma or the passenger leukocyte population. Regardless of the technique 
used. the important concept was tha t depletion of allogeneic passenger leukocytes led to 
prolonged allograft survival. 
Lechler and Batchelor [40] provided a key piece of evidence bringing DC to the 
forefront as the passenger leukocyte prototype. They showed that the immunogenicity 
of long-surviving enhanced (AS X AUG)F I renal allografts retransplanted into sec-
ondary AS recipients could he restored hy the injection of as few as I x 104 to 5 X 104 
DC of donor strain derived from afferent lymph [40]. In contrast. neither the passenger 
volume of donor strain blood. nor 5 x 10° T- or B-lymphocytes were able to do so. 
thereby demonstrating more than a 100-fold difference in immunogenic potency. These 
findings were consistent with observations about the functional activities of DC origin-
ally made by Steinman and colleagues [41-43] and later confirmed by many others. 
Disrupted Local Lymphatics 
It should be remembered that donor organ harvesting and reimplantation disrupts the 
dferent lymphatic channels. This blocks an important migratory circuit for immune 
cells that are either already present in or enter the allograft interstitium. until connec-
tions with regional lymph nodes are reestablished within 2-3 weeks [44-48]. In fact. 
efferent lymphatic disruption. along with ischemic injury contributes to a 'reimplanta-
tion' response. which by itself can precipitate activation of the intraorgan immune 
network [46-51]. Thus. this purely mechanical problem can. in some respects. simulate 
an antigen-driven immune response [51] and is one of the first difficulties. but by no 
means the only one. encountered when the immune system of the donor attempts 
assimilation with that of the recipient. 
The presence of MHC. adhesion and costimulating molecules on DC causes them to 
spontaneously form clusters with and directly activate allogeneic lymphocytes [24.52]. 
In an allograft. activated recipient T cells in such clusters proliferate [24] and produce 
cytokines that recruit other immune cells that have the potential to damage the organ. 
In fact. the distribution of mononuclear cells at the initiation of acute rejection reflects 
the intraorgan distribution of DC [24.52]: in kidney allografts it preferentially localizes 
to the cortex and outer medulla [14. 15]. whereas. in the liver. portal tracts and peri-
venular regions are preferentially targeted [17.24,53]. Conversely. the absence of renal 
cortex or portal tracts in an allograft kidney or liver biopsy. respectively. renders such 
samples inadequate for the evaluation of rejection. Altogether. this process is referred 
to as 'peripheral sensitization'. or recognition of the allograft in the periphery via direct 
alloantigenic stimulation. Subsequently, upregu!ation of adhesion molecules on the 
surrounding vasculature and recruitment of lymphoid and nonlymphoid effector cells 
and local tissue damage signal the development of acute 'cellular' rejection. 
In organs with mucosal-associated lymphoid tissue, such as the lung and intestines, 
recipient lymphocytes trafficking into the allograft following the same migratory routes 
as they normally would: they enter the T cell-dependent areas of the bronchial (BALT) 
and mucosal (MALT) associated lymphoid tissue. respectively [12.54-58]. Here they 
encounter donor DC and participate in a bidirectional . ill l'il'O mixed leukocyte 
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response' [12.54-59]. which is the same type of response as described ahove for the 
interstitium of organs except that the surrounding microenvironment contains 
immunologically active donor T- and B-lymphocytes. 
Passenger Leukocytes 
Passenger leukocytes from the donor immune network. including DC. leave the allo-
graft. either hematogenously or via intact regional efferent lymphatics that drain to 
c/ol/or regional lymph nodes transplanted ('1/ h/ol' with the allograft [56.57.59]. Larsen 
and colleagues [60.61] were the first to show that donor DC frol11 a heart allograft 
migrate hematogenously to the recipient spleen. The same thing occurs after transplan-
tation of a liver allo- or xenograft [24.62]. Donor DC leaving these allografts migrate to 
the periarterial lymphatic sheath and marginal zone of the spleen. where their appear-
ance is associated with a proliferative response in the recipient lymphoid cells (Plate 
20.1) [24.63]. Altogether. this process is referred to as 'central sensitization' 
[24.60.61.63]. or central recognition of the allograft. again via direct alloantigenic 
stimulation. The passenger leukocyte population also contains hematopoietic stem 
cells. as well as T and B cells. macrophages. and mature and progenitor DC <Plate 
20.2). This is evidenced hy their ability to reconstitute lethally irradiated experimental 
animal recipients [4.5] and to convert the blood type of human recipients [64]. Thus. at 
the progenitor level. donor cells will have access to the recipient bone marrow. to 
regional and distant lymph nodes. and even to the thymic medulla [3.63.65-68]. 
Once recipient T cells are activated within the allograft and rejection effector mechan-
isms begin to damage the organ, there is an increased production of lymph and 
disruption of the lymphatic and capillary microvascular endothelial junctions. This 
retards immune cell traffic and lymph fiow [45-4l:i. 69-71] and contributes to the re-
appearance of graft edema and swelling typically seen during acute rejection [45. 69-72]. 
The result is an endless cycle of immune activation and damage. graft edema. retarded 
immune cell trafficking and diminished blood flow. Unless interrupted by increased 
immunosuppression. the process usually leads to allograft failure. 
Considering the completeness of the data outlined above. it was reasonable to con-
clude that the passenger leukocyte popUlation should he removed from the allograft 
before transplantation. Thus. various types of irradiation [73] and monoclonal anti-
bodies directed at common leukocyte (74-76] or MHC class II [77-79] antigens were 
used in an effort to deplete these cells. In general. all of these pretreatment regimens 
prolonged allograft survival. but the long-term beneficial effects were less than expected. 
Targeting Donor DC 
Blocking costimulatory molecules such as the B7 family [80-85] and CD40 [81. 86] 
interrupts cell signaling mediated by interactions of these molecules with their ligands 
and significantly diminishes acute rejection. resulting in prolongation of graft survival 
[SI-88]. In some models. there is even an absence [81] or amelioration of chronic 
rejection (CR) [82-86]. However. in some of the models used. CR develops directly 
from acute rejection. which is nonlethal because of genetic compatibility between the 
donor and recipient [83-85]. and may not reflect the clinical scenario in most cases of 
CR (89]. I n addition. the presence of infiltrates within the treated allografts [S2. 84] or 
I . ~""DKD "... ~KKK . ~DK -. f ;j~ D:K:;I::I!=~::--K~D:-D ~~-
I 
. . ~~ K~KD : 
344 A.J. Demetris et al . 
actual allograft \'asculopathy [82-85] suggests that tolerance without a susceptibility to 
CR has not been achieved. Nevertheless. this line of research represents an important 
advance in our understanding. of how acute rejection damages an allograft. 
It is interesting to note that the beneficial effect of costimulatory molecule blockade 
was dimillished by immunosuppression and was augmenTed by the addition of donor 
antigen in the form of donor splenocytes [85]. In addition. the B7-CD28 blockade does 
not completely stop cytokine mRNA production within the allog.raft. Instead it is 
shifted toward a T H2-type 'tolerogenic' pathway [87]. Paradoxically. the beneficial effect 
is still observed in IL-4 deficient mice [88]. These observations suggest. but do not 
prove. that tolerance requires T cell activation. and that stimulation is best provided 
by the passenger leukocyte population [36.90.9\]. 
Nonetheless. the logical conclusion of this line of reasoning is to construct allografts 
completely devoid of passenger leukocytes. The idea is that the stimulatory DC are 
removed and forms of donor antigen other than hematopoietic cells. such as the allo-
graft parenchyma and stroma [25.92.93] and soluble MHC antigens [94.95] or peptides 
[94-97]. may actually be tolerogenic [90]. Although this line of reasoning has several 
important conceptual flaws. it is based on the concept that more than one signal is 
needed to trigger T cell activation and proliferation [25]. 
III I'ilm. presentation of antigen without proper costimulation can result in anergy 
[25]. When this concept is tested ill l'il'O using transgenic mice. the results are not clear 
cut. tor example. the immune system of mice carrying allogeneic MHC transgenes on 
nonimmune cells. such as islets of Langerhans. simply 'ignores' alloantigen expression 
until it is presented to the immune system in the proper context by DC and other 
antigen-presenting cells. This most often occurs during tissue damage from viral infec-
tion or other insults that cause local immune stimulation [98-100]. 
In a vascularized allograft. immune activation. and thus immunological cognition of 
the allograft. is extremely difficult, if not impossible to avoid. Organ harvesting and 
reimplantation. ischemia, preexisting donor diseases and efferent lymphatic disruption 
can all potentially contribute to intragraft immune activation. which in turn creates an 
immune environment conducive to allorecognition. even if donor DC are not present. 
Migration of potently allostimulatory cells from the allograft assures central allorecog-
nition. Thus. from a practical perspective in clinical transplantation. it is our opinion 
that. initially. very few allografts are 'ignored', which is evidenced by the fact that all 
allograft recipients require immune suppression to prevent acute rejection. 
Nevertheless. certain tissue allografts. such as pure epithelial [35. 10 \. 102]. fibroblast 
[103]. and corneal [104] allografts. can be completely depleted of donor hematopoietic 
cells. Unfortunately. these allografts are still often rejected [35. IO\. 102]. particularly if 
they are placed into an immunologically active environment [105]. similar to the obser-
vations described above for the transgenic mice. Thus. despite an absence of passenger 
leukocytes or DC. rejection still occurs. albeit more slowly. and probably via the 
indirect pathway of alloantigen presentation [35, 104.106-109]. 
Transitional Phase 
Since passenger leukocytes are bone marrow-derived or stem cell-dependent. they exist 
for a relatively short period in the periphery. Thus. replacement of the donor intraorgan 
immune network (including DC) after transplantation with similar recipient cells is an 
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expected finding [57. 110-118]. Indeed. this occurs to some extent in all allografts. since 
trafficking of immune cells is part of the normal 'nonlocal' immune physiology. How-
ever. as discussed above. when recipient T cells encounter donor DC (and vice versa). 
the transitional process has to be chaperoned by immunosuppressive drugs because it 
usually precipitates acute rejection. For DC. the replacement phenomenon likely occurs 
at a precursor cell stage. since mature recipient DC do not appear to home to allograft 
tissues [119]. 
It is likely that the same factors that control activation. maturation. and migration of 
DC precursors in nonallograft organs contribute to donor and recipient DC trafficking 
in allografts. For example. it is known that the intraorgan cytokine milieu contributes 
to activation. recruitment. and migration of both macrophages and DC. In allografts. 
the cytokine-rich milieu of rejection [120] quickens the rate and extent of donor macro-
phage replacement [II\, 121]. Infiltrates associated with T HI-type cytokines. such IFN-
"f and macrophage-activating chemokines like IL-12. mobilize donor macrophages and 
foster the influx of activated recipient cells (unpublished observation). 
An orderly transition from donor to recipient cells in the intraorgan immune net-
work. however. is dependent on preventing architectural damage during the transition 
[57]. If this can be accomplished. recipient cells can function alongside donor ones. as a 
chimeric intraorgan immune network. If not. irreversible structural damage may pre-
vent reestablishment of a normally functioning intraorgan immune network. with lines 
of communication to regional lymph nodes. The architectural damage can occur at the 
level of the BAL T [116, 122. 123] or GALT [57. 118, 124]. lymphatic drainage from the 
organ. and/or the regional donor lymph nodes [57]. Subsequently, any cause of allo-
graft inflammation, such as environmental irritants or infection, may result in an inef-
fectual local immune response and persistence of the insu\t(s). This. in turn, can cause 
cytokine release that facilitates alloimmune injury, and the allograft then becomes 
trapped in a relentless downward spiral of declining organ function that eventually 
ends in allograft failure (see below). 
Chronic Rejection 
Chronic rejection (CR). in any organ, can be broadly defined as a largely indolent but 
progressive form of allograft injury. characterized primarily by persistent but patchy 
inflammation of the allograft. interstitial fibrosis. fibrointimal hyperplasia of arteries. 
and destruction and atrophy of parenchymal elements and organ-associated lymphoid 
tissue [89. 120, 125]. The term chronic implies a temporally prolonged course and. in 
general. CR more indolently compromises organ function than acute rejection. How-
ever. it clearly develops in many cases from inadeq uately controlled acute rejection and 
in patients not compliant with immunosuppressive therapy. In others, CR more indo-
lently compromises allograft function over a period of months to years. without an 
apparent precipitating event [89]. Our emphasis here will be on DC. The reader inter-
ested in a broader perspective of CR is referred to several recent reviews [89, 126-128]. 
The intragraft inflammatory infiltrates associated with CR are often arranged into 
nodular aggregates, some of which contain germinal centers [89] reminiscent of the 
development of mucosal-associated lymphoid tissue. discussed above. Immunopheno-
typic analysis reveals a predominance of CD4+ and CaU~ T cells and macrophages 
with fewer B cells. although those present can form small primary and secondary 
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follicles. This is in contrast to the infiltrates associated with acute rejection. which have 
fewer B cells and no follicles and tend to be more diffusdy distributed throughout the 
interstitium. lacking an organized structure. 
Few studies have specifically investigated DC in chronically rejecting organs. Oguma 
('I al. (129) suggested that DC of r('cipi('1It origin participated in the CR process by 
coordinating antigenic presentation in arteries affected by obliterative arteriopathy 
and in the interstitium. Subsequent studies have verified these findings and found 
that the number or recipient DC in chronically rejecting organs correlates directly 
with the overall severity of inflammation [116. 120. 130]. Moreover. the r('cipi(,1I1 DC 
are concentrated amidst the lymphoid aggregates [116.120.122.129]. suggesting that 
they arc coordinating antigen presentation. an assumption based on the spatial rela-
tionship between the DC and the lymphoid infiltrates. These morphological and immu-
nohistochemical observations are consistent with the concept that indirect (rather 
than direct). MHC-restricted alloantigen presentation importantly contributes to CR 
[I06-IOX]. and that chronic antigenic stimulation occurring outside the lymph nodes 
can result in the development of intraorgan lymphoid tissue [131. 132]. similarly to 
autoimmune disorders such as Hashimoto's thyroiditis. primary biliary cirrhosis. and 
Crohn's disease [131]. 
As alluded to abovc. chronically rejecting allografts also devdop another significant 
problem: thc persistent or severe injury during the transitional phase selectively 
damages mucosal-associated lymphoid tissue normally present in the lung [12. 133] 
and intestines [56.58] and focally disrupts intraorgan lymphatics in other organs 
[46.89. 120]. Eventually these structures can be completely destroyed and replaced by 
fibrosis [56.58. 133. 134]. Consequently. the organizational structure of the immune 
network and migratory routes of DC are disrupted. This undoubtedly contributes to 
the inability of the intraorgan immune network to adequately process infectious and 
other antigens. Thus. it is tempting to speculate that this accounts for the frequent 
association between infection and CR [123. 133. 135-139]: chronically rejecting organs 
may simply be unable to adequately handle infections or other antigenic insults. 
HEMATOLYMPHOID ANO OENDRITIC CELLS AS FACILITATORS OF TOLERANCE 
INDUCTION 
There are two lines of transplantation research in which studies show how donor 
hematopoietic cells in general. and DC specifically. might induce tolerance to solid 
organ allografts. The first of these is activation-induced clonal deletion and the second 
is induction of hematopoietic chimerism. 
Donor Dendritic Cells as Mediators of Peripheral Clonal Deletion 
Implantation of any solid organ allograft results in a characteristic cycle of heightened 
immune activation. followed by evolution toward a more stable relationship between 
the allograft and the recipient when immunosuppression can be considerably lowered or 
even withdrawn [140.141]. With the understanding brought about by the appreciation of 
donor hematopoietic cell migration after transplantation [24.63. 113. 142]. this proto-
typic series of events can likely be attributed. in large part. to the initial engagement of 
donor and recipient immune cells in the allograft and recipient lymphoid tissues. 
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During this time. it is possible that the intense immune activation results in a form of 
clonal deletion called clonal stripping [143]. deletion or purging through apoptosis 
[144-146]. It might be crudely thought of as the peripheral equivalent of negative 
selection in the thymus. which is a very efficient means of controlling reactivity in a 
lymphocyte population. Current research suggests that DC may he involved in this 
process: blocking of costimulation on mature DC allows exhibition of their apopto-
sis-inducing potential and they thus may be particularly adept at mediating such a 
process [27.147.148]. In fact. it is tempting to speculate that the combination of clonal 
deletion via apoptosis after a strong rejection reaction. followed by replacement of the 
intra-graft immune network (graft adaptation). ultimately causes the immune system to 
ignore the allograft. 
Unfortunately. on a practical level. the harsh reality is that. even in combination. the 
above mechanisms are unable to prevent rejection in the majority of long-term survi-
vors without the aid of exogenous immunosuppression [89]. At best. there exists an 
uneasy truce between an adapted allograft and a recipient that can be triggered into a 
rejection reaction at the slightest provocation. I n the worst case. most long-term reci-
pients are slowly rejecting their organs. This also holds true for liver allograft recipients. 
who are resistant to CR compared to recipients of other vascularized allografts 
[89. 149]: even this 'favorable' recipient population requires chronic immunosuppres-
sion in over 80% of long-term survivors [141]. Thus. while clonal deletion or stripping. 
veto or regulatory cells. or other mechanisms may contribute to graft acceptance in 
immunosuppressed recipients. they are insufficient in the majority of patients to allow 
cessation of immunosuppressive therapy. 
Dendritic Cells as Mediators of the Effects of Hematopoietic Chimerism 
Owen [150] was the first to show that twin cattle sharing a placental circulation develop 
chimeric immune systems. each composed of immune cells from both individuals [150]. 
He found that this condition enabled them to exchange other tissues without the fear 
of rejection. or a need for immunosuppression. When attempts were made to create 
chimeric immune systems in adult animals. it was quickly realized that lethal or sub-
lethal irradiation and other harsh conditioning regimens were required to ablate the 
recipient immune system and to make 'physiological space' for the engraftment of 
infused donor bone marrow [151-159]. Unfortunately. this limits clinical implementa-
tion of the concept. Two major problems exist: graft-versus-host disease [160. 161) and 
the morbidity associated with the conditioning regimens [158. 162]. Current approaches 
to decreasing morbidity without compromising donor stem cell engraftment include 
lower doses of irradiation. facilitator cells [163. 164]. and/or higher doses or repeated 
infusions of donor bone marrow [159. 162. 165]. 
Nevertheless. when donor stem cell engraftment results in long-term mixed hemato-
poietic chimerism. there is complete assimilation of the donor immune system in some 
cases. and an undeniable association with tolerance. In the mixed chimeric animals. 
intraorgan immune networks are composed of cells from both individuals [154, 166]. 
and tolerance is strictly dependent on the persistence of hematopoietic chimerism: loss 
of chimerism and loss of tolerance go together [167. 168]. This has been observed in 
humans given fetal liver cell allografts [169-171]. and in a number of small experimental 
animal models [151-155.157-159]. 
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The experimental models ha\'e been useful in determining the role of DC in tolerance 
induction. For example. mixed chimeric animals specifically lack donor responsiveness 
in a MLR. accept allografts without immunosuppression. and arc resistant to CR 
[I n. 173]. Central deletional tolerance is primarily responsible for these observations 
[154. 155. 158]. although peripheral mechanisms also likely contribute to the process 
[174. 175], Thus. the situation is similar to the nontransplantation setting. where both 
central and peripheral mechanisms contribute to 'self' tolerance. which is a 'local' 
property of the immune system. 
In the nontransplantation setting. central or thymic tolerance invol\'es a complex set 
of thymic epithelial and stromal interactions with immature T cells that first mediate 
positive selection of developing thymocytes. based on 'self' reactivity [176-179], Sub-
sequently. thymic medullary DC play a predominant role in negative selection 
[176. 178. 180-186]. where cells that react too strongly with the DC are deleted. Similar 
observations have been made in the mixed allogeneic chimeras: thymic stromal and 
epithelial elements appear to mediate positive selection. even if there is MHC mismatch-
ing between the lymphoid and non lymphoid popUlations [169. 171. 187]. whereas donor 
thymic hematopoietic cells appear to mediate negative selection [158. 166. 168. 169. 
17\. 174. 187]. Although more studies are needed to identify the popUlation of donor 
cells that mediate negative selection in chimeras. the characteristics identified to date 
make donor DC a likely candidate [3. 63. 65-68]. 
FINDINGS THAT BRIDGE THE GAP BETWEEN IMMUNOGENIC AND 
TOLEROGENIC DC 
In the late 1980s. a series of experiments were carried out to examine the sequence of 
histopathological changes associated with acute intestinal allograft rejection [56. 57]. 
During these studies. it was necessary to distinguish between donor and recipient 
lymphoid cells. so that one could unravel the underlying immune pathophysiology. 
This was achieved with the development of a monoclonal antibody that reacted with 
the class II major histocompatibility antigens of most rat strains. except the Brown 
Norway (BN) [188]. Subsequently. it was possible to show that Lewis cells emigrated 
into the BN GALT and mesenteric lymph node of intestinal allografts. where they 
replaced cells of donor origin in the organ-based immune network. This occurred 
within the first several weeks after transplantation [57]. Similar findings were observed 
in human small-intestinal allograft recipients [112]. 
The above studies prompted an investigation of the fate of donor cells that had 
emigrated from the allograft. Up to that time. very few such studies had appeared in 
the literature [24. 60. 65. 189. 190]. and all came to the same conclusion discussed 
above-donor passenger leukocytes. especially DC. were essentially deleterious to allo-
graft survival because they served only to precipitate and/or amplify a rejection reac-
tion. However. all of these studies were conducted in nonimmunosuppressed recipients, 
which resulted in rapid rejection of the allografts. as expected. Had similar studies been 
carried out on the fate of passenger leukocytes in either transiently or continuously 
immunosuppressed recipients. the conclusion about the role of DC in organ transplan-
tation might have been different. In essence. that is what was done in the early 1990s. 
A quick survey of available long-term experimental animal and several humans 
organ allograft recipients revealed a surprising finding-the donor hematolymphoid 
~K D:~~; I:I~::I~~~: ',::,:.;: 
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cells persisted in long-term survivors (Plate 20.3). some of whom were chronically free 
of immunosuppressive therapy [65. 113. 166]. Moreover. the donor cells were ubiqui-
tously distributed throughout the lymphoid and nonlymphoid tissues. and some had the 
characteristics of DC [65. 166]. This included a strong surface expression of MHC class 
II antigens. a dendritic shape. and a location in the interstitium of organs. the para-
cortex of lymph nodes. the thymic medulla [63. 65-68]. and the periarterial lymphatic 
sheath of the spleen. These are all sites where DC normally reside. Further studies by 
Lu and Thomson [21. 66. 191. 192] showed conclusively that DC and their precursors 
were included among the passenger leukocytes persisting in organ allograft recipients. 
These observations led to the suggestion that 'microchimerism' or the persistence of 
donor hematopoietic cells was necessary. but alone not sufficient. for the induction of 
tolerance [I 13-115.193]. Since the donor cells persisted for decades in some patients. it 
was assumed that they are sustained by 'engrafted' donor stem cells transplanted with 
the organ (Plate 20.2). The important conceptual point is that donor hematolymphoid 
cells appear to have integrated successfully into the recipient immune system. similarly 
to the chimeras made by irradiation. However. the number of donor cells present is 
much smaller in microchimeras than in macrochimeras made by irradiation. and this 
likely affects the relative contribution of various mechanisms to the tolerant phenotype. 
For example. it is unlikely that only a few donor DC that make their way to the 
recipient thymus would be able to completely delete donor reactive T cells (Plate 
20.3). but there may be enough to activate autoregulatory circuits. In the meanwhile. 
other studies confirmed that passenger leukocytes persisted in experimental animals 
and in humans. but the authors did not necessarily agree with our interpretation 
[92.93, 194-201]. 
I nitially this discovery did not fit easily into the current understanding of donor DC 
in transplantation immunobiology. It was not immediately clear how the most poten-
tially potent allogeneic simulator could survive long term in a recipient who no longer 
required immunosuppression. This was especially true for DC in the periphery, even 
though freshly isolated DC from non lymphoid tissues are relatively inefficient antigen-
presenting cells. It was clear, however. that long-term persistence of donor DC in the 
allograft was associated with freedom from chronic rejection [120] and, therefore, they 
might mediate tolerogenic reactions. In addition. trafficking of donor hematopoietic 
stem and progenitor cells from the allograft to the recipient bone marrow and thymus 
was not widely appreciated. However. analogies were drawn between this situation and 
that of mixed allogeneic chimeras achieved with irradiation. In the periphery. only a few 
studies had suggested that DC might mediate tolerogenic reactions [202, 203]. More 
recently. however. there is an increasing awareness that DC can and do mediate even-
tual 'nonresponsiveness' [21. 204-207]. How this is achieved is covered in greater detail 
in Chapter 26. 
In the non transplantation setting, there is now convincing evidence that DC can 
mediate both stimulatory and tolerogenic immune reactions. The context of presenta-
tion is certainly of great importance in determining which pathway is chosen. This is 
also true for transplantation. Without transient immunosuppression. mature DC 
invariably precipitate rejection that causes graft failure. With immunosuppression. 
acute rejection is avoided and the persistence of donor DC is associated with allograft 
protection from CR [120]. These probably arise from engrafted stem cells and/or other 
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precursors. Emerging details about the mechanism(s) in stimulatory and tolerogenic 
reactions invol\ed are cmered in Chapter 26. 
What. then. has been learned ahout the immune system. MHC antigens and the role 
of DC in the experimcnt of transplantation'! First. it is dear that an immune system has 
'Iocal" properties. which greatly complicate the ability to take an organ from one person 
and implant it into another one. We have also learned that MHC antigens and DC both 
play important roles in defining these local properties. and successful long-term free-
dom from rejection prohahly requires transfer of the donor immune system. DC appear 
to exert this etlcct via their ability to stimulate immune reactions that either prevent or 
1~lcilitate assimilation of the donor immune system and its accompanying organ into the 
recipient. which in turn depends on their phenotype and maturational stage. Thus. in a 
generic sense. at least part of the 'Ioca r properties of the immune system are self-defined 
by DC. and the other immune cells with which they interact. both in the thymus and in 
the periphery. However. this occurs in the context of the environment and is dependent 
on. but not strictly limited hy. the recipient MHC genes,antigens. Consequently. it 
appears that the local properties of the immune system and MHC antigens were not 
designed for the purpose of preventing allogeneic transplantation but to enable species 
adaptability [20X-210]. The key to understanding. and thus controlling. the immune 
system for the purpose of transplantation will come from a knowledge of its local and 
nonlocal properties so that the latter can be exploited [90. 211]. 
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Plate 19.4. Juvenile xanthogranuloma family. (A) 12-year-old girl had meningitic involvement. (B) 
Fascin immunostain is strongly positive on JXG cells. 
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Plate 20.1. Identification of donor cells in the recipient spleen and thymus. Series of photomicrographs taken 
from sections of the recipient spleen (all except upper right frame) and thymus (upper 
right frame), 3 days after transplantation of a rat liver allograft. The recipients were treated with immunosup-
pression and all of the tissues are stained with a monoclonal antibody that reacts with 
MHC class II antigens of the donor, but not that of the recipient [188]. Note the presence of donor cells in the 
marginal zone and B cell follicles in the spleen in the upper left, lower left and lower right frames. Donor MHC 
class W cells are also detected in the thymic medulla (upper right). In the lower right 
frames, the tissue is also stained for BrdU, which labels cells synthesizing DNA. Note that the presence of 
donor cells in the recipient spleen is associated with proliferation of both cell populations (63). 
Plate 20.2. Donor CFU-C in recipient bone marrow. Photomicrographs of a cOlony-forming unit-culture (CFU-C) 
assay using a fibrin clot system. The cultured cells were obtained from the bone marrow of a recipient rat, 10 
days after liver transplantation, and stained for donor MHC class II antigens. Note the presence of donor 
hematopoietic colonies on the right. On the left, note the presence of myelomono-cytic cells, some of which have 
a characteristic dendritic morphology, typical of rat dendritic cells [212,213). 
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Plate 20.3, Donor dendritic cells within recipientthymus. Thymus of a rat liver allograft recipient. 30 days after 
transplantation. The tissue is double stained for donor MHC class II-positive cells (rust color) and ED2 (blue). 
which highlights tissue macrophages. Note the presence of the donor dendritic-shaped cell in the recipient thy-
mus (arrow and inset). The 'shrunken' medulla in this recipient can be attributed to the transient 2-week course 
of FK506, which is known to cause damage to the thymic medulla [214]. It may also create a milieu conducive to 
the recruitment of donor DC progenitors [3, 214). (B) Donor DC can also be detected in the spleen. This is a sec-
tion of recipient spleen, obtained 30 days after liver transplantation and double stained for donor MHC class II 
(red) and OX62, an integrin, known to be expressed by rat DC [213]. Note the presence of the yellow, doubly 
labeled donor DC. (C) Challenge donor heart allograft 100 days after transplantation in a recipient rendered tol-
erant to the donor by a previous liver allograft. This section is double stained for donor MHC class II (red) and 
OX62. Note the red, single positive MHC class W donor interstitial cell (large arrow) and yellow, double positive 
donor DC. Even though this recipient received no immunosuppression, donor DC persisted in the challenge allo-
graft and it was resistant to chronic rejection (120). 
